DoJ Pseudoephedrine Suit Seeks Up To $145.6 Mil. From NBTY
This article was originally published in The Tan Sheet
Executive Summary
The U.S. Department of Justice's office for the Eastern District of New York is seeking up to $145.6 mil. in fines from dietary supplement manufacturer NBTY in response to recordkeeping and reporting violations the firm allegedly committed with regard to mail order shipments of pseudoephedrine-containing OTCs
You may also be interested in...
Pseudoephedrine Retail Purchase Uniform 9 Gram Threshold Proposed In Bill
Retail purchases of "combination ephedrine products" would be limited to 9 g per transaction by legislation introduced in the Senate to curb the illegal production and distribution of methamphetamines
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands